19 February 2020 - Deborah Wilkes
Archived
The US Food and Drug Administration (FDA) has switched GlaxoSmithKline’s (GSK’s) topical pain reliever Voltaren (diclofenac sodium topical gel 1%) from prescription-to-OTC status. GSK said the OTC version, called Voltaren Arthritis Pain, would be “available on US shelves in spring 2020”.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.